A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer (Q39676808)

13 September 2017

A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer (English)

1 reference

13 September 2017

1 reference

Weihua Yin

1

1 reference

13 September 2017

Qiushan He

2

1 reference

13 September 2017

Zhiming Hu

3

1 reference

13 September 2017

Zhong Chen

4

1 reference

13 September 2017

Mao Qifeng

5

1 reference

13 September 2017

Song Zhichun

6

1 reference

13 September 2017

Qu Zhihui

7

1 reference

13 September 2017

Nie Xiaoxia

8

1 reference

13 September 2017

Jinlong Li

9

1 reference

13 September 2017

Jimin Gao

10

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

13 September 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

13 September 2017

28

1 reference

13 September 2017

31

1 reference

13 September 2017

4937-4944

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

13 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Vaccination with allogeneic GM-CSF gene-modified lung cancer cells: antitumor activity comparing with that induced by autologous vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Formalin-fixed tumor cells effectively induce antitumor immunity both in prophylactic and therapeutic conditions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Prevention of de novo prostate cancer by immunization with tumor-derived vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

GM-CSF-surface-modified B16.F10 melanoma cell vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

The dendritic cell system and its role in immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Biological functions of tumor necrosis factor cytokines and their receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Tumor necrosis factor, cancer and anticancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Immunomodulation by semi-mature dendritic cells: a novel role of Toll-like receptors and interleukin-6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Identity of differentiation inducing factor and tumour necrosis factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Comparison of snap freezing versus ethanol fixation for gene expression profiling of tissue specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Helping the CD8(+) T-cell response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Antigenic targets for renal cell carcinoma immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Understanding the dendritic cell lineage through a study of cytokine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Active uptake of dendritic cell-derived exovesicles by epithelial cells induces the release of inflammatory mediators through a TNF-alpha-mediated pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

Leuprolide with and without flutamide in advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.05.038

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.05.038

1 reference

release_x2hjg6di2vfe5kclmkog7egs3e

13 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/x2hjg6di2vfe5kclmkog7egs3e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference